Your browser doesn't support javascript.
loading
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.
Bonacci, R; Gigliotti, A; Baudin, E; Wion-Barbot, N; Emy, P; Bonnay, M; Cailleux, A F; Nakib, I; Schlumberger, M.
Afiliação
  • Bonacci R; Institut Gustave Roussy, Villejuif, France.
Br J Cancer ; 78(4): 546-9, 1998 Aug.
Article em En | MEDLINE | ID: mdl-9716042
ABSTRACT
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Neoplasias do Córtex Suprarrenal / Etoposídeo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 1998 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Neoplasias do Córtex Suprarrenal / Etoposídeo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 1998 Tipo de documento: Article